MyPeptideHelper

Goal

Injury repair

Compounds15
With human trials2

Two compounds carry this list, and both of them are animal data wearing a confident face.

Injury repair is kept separate from joint and tendon health because the situations differ. This page is for something acute or subacute with a known site and a plausible healing timeline — a strain, a wound, a post-surgical recovery — where you run a time-limited course and then stop. Chronic degenerative complaints belong on the joint and tendon page instead.

BPC-157 and TB-500 sit at 5/5, and together they are the clearest example on this site of a strong match against a weak evidence base: both have extensive rodent tendon, ligament and gut healing data, and essentially no controlled human dosing trials. Beneath them a broad band at 3 covers the growth hormone axis compounds supporting collagen synthesis and local repair, plus GHK-Cu and LL-37, whose best evidence is in wounds and skin rather than deep tissue. A 2 tier including KPV and ARA-290 works on the inflammatory side of healing rather than the rebuilding side.

Two practical filters before you compare anything here. First, get the diagnosis: no peptide reduces a full-thickness tear that needs a surgeon, and several months on the wrong protocol is a worse outcome than an awkward scan appointment. Second, graded loading is the intervention with the actual evidence behind it in tendon and muscle rehab; anything on this page is at best an adjunct to that. Note too that TB-500 is banned by WADA and that anything promoting tissue growth is contraindicated in active malignancy.

How to read this

Match — how squarely it aims here

The weight the dataset gives this compound for this goal, 1 to 5. It describes intent and mechanism, not benefit, and not direction: a 5 means the compound acts hard on the system in question.

5/5Match strength 5 of 5primary use

Evidence — whether anyone has shown it

Read from the compound’s evidence note and handling grade, for the compound as a whole rather than for this goal alone. A 5/5 match on animal data is a hypothesis, not a result.

  • Human trialsRandomized or controlled human trials exist, or the compound holds a regulatory approval somewhere. Trials existing is not the same as trials succeeding — some of these were negative.
  • Some human dataPublished human work exists but is small, early-phase, acute, or from a single group that nobody has replicated.
  • Animal data onlyThe case rests on rodent and cell work. Doses shown are extrapolated, not established in people.
  • Anecdotal onlyNo published trial record of any kind. Every number comes from vendor packaging and community practice.

15 compounds, strongest match first

Ranked for injury repair

Match 5/5 · Primary use

2

Match 3/5 · Meaningful contributor

8

Match 2/5 · Marginal

5

Named stacks

Protocols built around this goal

KLOWPrimary goal8 weeksIntermediateA fixed four-peptide healing blend sold in a single vial: GHK-Cu, BPC-157, TB-500 and KPV. It is the older GLOW blend (GHK-Cu + BPC-157 + TB-500) with KPV added, which is where the leading K comes from. Run as one daily subcutaneous shot for soft-tissue repair, gut and skin work.Wolverine StackPrimary goal8 weeksBeginnerThe classic two-peptide repair stack: BPC-157 daily for local tendon, ligament and gut healing, plus TB-500 loaded twice weekly for systemic cell migration and tissue remodeling. The most commonly run injury protocol and the base that KLOW was built on top of.GLOW 42Also targets4 weeksIntermediateA fixed three-peptide repair and skin blend sold in a single 42 mg vial: GHK-Cu, BPC-157 and TB-500. This is the original GLOW blend, and it is exactly KLOW with the KPV left out - KLOW is GLOW plus KPV, which is where the leading K in KLOW comes from. Run as one daily subcutaneous shot for skin, soft tissue and connective tissue work.GH Pulse (Ipamorelin + CJC-1295 no-DAC)Also targets12 weeksBeginnerThe standard growth hormone secretagogue pairing: a GHRH analogue (CJC-1295 without DAC, also sold as Mod GRF 1-29) plus a ghrelin receptor agonist (ipamorelin), injected together so the two mechanisms produce a larger pulse than either alone. Both are short-acting, which is the point - it mimics a natural pulse instead of flattening it.

Not sure this is your goal

Most people arrive wanting two or three of these at once, and the honest answer is usually to pick one and run it properly. The quiz weighs your goals against your experience, the routes you will tolerate and your contraindications, then shows its reasoning rather than just a name.

Take the quiz

Other goals

Educational information only, not medical advice. Talk to a licensed clinician before starting, changing, or stopping anything.